| Assessment Status | Rapid Review Complete |
| HTA ID | 24051 |
| Drug | Mirvetuximab |
| Brand | Elahere® |
| Indication | Mirvetuximab soravtansine (Elahere®) is indicated as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. |
| Assessment Process | |
| Rapid review commissioned | 17/12/2024 |
| Rapid review completed | 04/02/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Mirvetuximab soravtansine compared with the current standard of care. |
